We've had the opportunity to evaluate the CD34+ cell in the past 20 years, and finally we have a tool that represents a potential breakthrough for patients with CMD, said Douglas Losordo, MD, FACC, FAHA, chief medical officer at Caladrius Biosciences.
We've had the opportunity to evaluate the CD34+ cell in the past 20 years, and finally we have a tool that represents a potential breakthrough for patients with CMD, said Douglas Losordo, MD, FACC, FAHA, chief medical officer at Caladrius Biosciences.
Transcript
As 1 of the scientists who found the CD34 cells 20 years ago, how has research and treatment evolved since its discovery?
In the past 20 years, we've had the opportunity to evaluate the ability of the CD34 cell to institute repair in patients who have suffered some sort of ischemic insult, whether it's a heart attack, heart failure, limb ischemia, or in the most recent case, coronary microvascular dysfunction, that's causing chest pain. The fascinating thing about this cell is that it has an unblemished track record, in terms of showing evidence for clinical benefit in every setting in which it's been tested. So, it's been quite interesting and quite encouraging, and we're now really approaching the point where these cells will be made available as part of the toolkit that doctors will have to treat patients with cardiovascular disease.
Can you describe the importance of treating CD34 cells in patients with CMD to lessen the risk of related adverse clinical outcomes?
Coronary microvascular dysfunction, or CMD, has only recently started to become recognized as a critical component, and perhaps the most important component that confers risk to patients with heart disease. We know that measurements of coronary microvascular dysfunction correlate with bad outcomes in patients. The worst your CMD, the higher the risk of cardiovascular events. What we do not yet know is whether improving coronary microvascular function results in a decrease in risk—kind of like blood pressure. Before we had blood pressure medicines, we knew that having high blood pressure was bad. We just didn't know if lowering blood pressure would reduce the risk of events–now we know that. Finally, we have a tool, as evidenced by this recent study, that appears to improve coronary microvascular function. So, now we'll be able to see what happens if we improve function–does that result in a decrease in bad events. So, we'll be able to answer that question.
Award-Winning Poster Presentations From AMCP 2024
April 23rd 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, multiple poster presentations concerned with health equity, data collection, glucagon-like peptide-1 agonists, and more were acknowledged for their originality, relevance, clarity, bias, and quality.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
An Overview of Health Care and Pharmaceutical Trends, 2023-2024
April 19th 2024Douglas M. Long, BA, MBA, was featured as the keynote speaker on the closing day of The Academy of Managed Care Pharmacy 2024 annual meeting, with a session dedicated to surveying the health care and pharmaceutical trends of the last year.
Read More